{"id":"NCT02962648","sponsor":"Pharmacosmos A/S","briefTitle":"An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)","officialTitle":"An Open-label, Multicentre, Extension Trial to Assess the Safety of Re-dosing of Intravenous Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-01-09","primaryCompletion":"2018-06-12","completion":"2018-06-12","firstPosted":"2016-11-11","resultsPosted":"2020-03-10","lastUpdate":"2020-03-10"},"enrollment":103,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Iron Deficiency Anemia","Iron Deficiency Anaemia"],"interventions":[{"type":"DRUG","name":"Iron isomaltoside/ferric derisomaltose","otherNames":["Monofer®, Monoferric®, Monover®, Monofar®, Monoferro®"]}],"arms":[{"label":"Iron isomaltoside/ferric derisomaltose","type":"EXPERIMENTAL"}],"summary":"Evaluate safety and efficacy of intravenous (IV) iron isomaltoside/ferric derisomaltose re-dosing, in subjects who were previously treated with iron isomaltoside/ferric derisomaltose.","primaryOutcome":{"measure":"Number of Subjects With Adverse Drug Reactions (ADR)","timeFrame":"Baseline to week 26","effectByArm":[{"arm":"Iron Isomaltoside/Ferric Derisomaltose","deltaMin":5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":22,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":102},"commonTop":["Fatigue","Abdominal pain","Urinary tract infection","Dizziness","Headache"]}}